Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma MedDRA version: 19.0 Level: HLT Classification code 10041298 Term: Soft tissue sarcomas histology unspecified System Organ Class: 100000004864
Conditions
Sponsors
CytRx Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Has provided written informed consent prior to any study related activities. 2. Age =15 years (US only), and 18-80 (rest of world (ROW)), male or female. 3. Histological confirmation of intermediate or high grade soft-tissue sarcomaas determined by the local pathology report. Archival tissue must be sent to a central pathology lab for review but will not preclude entry onto the study (study-specific biopsies are not allowed). Final assignment of tumor grade and histology will be based on the designation provided by the central pathology review. 4. An adequate tumor specimen obtained by either excisional biopsy, incisional biopsy or core needle biopsy must be sent to the central pathology lab for evaluation. The material must measure at least 0.8 × 0.1 cm in size or contain at least 50 tumor cells. 5. Locally advanced, unresectable, and/or metastatic soft-tissue sarcoma of intermediate or high grade with evidence of disease progression by either computed tomography (CT) or magnetic resonance imaging (MRI) scan, or clinical judgment on or after the last cancer therapy within 6 months prior to randomization. 6. Relapsed or refractory (lack of response) to =1 course of systemic therapy regimen(s), excluding adjuvant or neoadjuvant chemotherapy, and is incurable by either surgery or radiation. 7. Capable of providing informed consent and complying with trial procedures. 8. ECOG PS 0-2. 9. Life expectancy >12 weeks. 10. Measurable tumor lesions according to RECIST 1.1 criteria. 11. Women must not be able to become pregnant (e.g., post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. (Adequate contraception includes: oral contraception, implanted contraception, intrauterine device implanted for at least 3 months, or barrier method in conjunction with spermicide.) 12. Males and their female partner(s) of child-bearing potential must use 2 forms of effective contraception (see Inclusion 11 plus condom or vasectomy for males) from the last menstrual period of the female partner during the study treatment and agree to continue use for 6 months after the final dose of study treatment. 13. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. 14. Accessibility to the site that optimizes the subject’s ability to keep all study-related appointments Are the trial subjects under 18? yes Number of subjects for this age range: 4 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 280 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 116
Exclusion criteria
Exclusion criteria: 1. Prior exposure to >375 mg/m2 of doxorubicin or liposomal doxorubicin. 2. Palliative surgery and/or radiation treatment within 30 days prior to date of randomization. 3. Exposure to any investigational agent within 30 days of date of randomization. 4. Exposure to any systemic chemotherapy within 30 days of date of randomization. 5. An inadequate tumor specimen as defined by the central pathologist. 6. Current evidence/diagnosis of alveolar soft part sarcoma, extraskeletal myxoid chondrosarcoma, rhabdomyosarcoma, osteosarcoma, gastrointestinal stromal tumor (GIST), dermatofibrosarcoma (unless transformed to fibrosarcoma), Ewing’s sarcoma, Kaposi’s sarcoma, mixed mesodermal tumor, clear cell sarcomas. 7. Evidence of central nervous system (CNS) metastasis who have not received prior definitive therapy for their lesions. 8. History of other malignancies except cured basal cell carcinoma, cutaneous squamous cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of the cervix unless documented free of cancer for =5 years. 9. Laboratory values: Screening serum creatinine >1.5 x upper limit of normal (ULN), alanine aminotransferase (ALT) >3×ULN or >5×ULN if liver metastases are present, total bilirubin >2×ULN, absolute neutrophil count (ANC) 16 meq/L (Central Laboratory) or arterial blood pH class II of the New York Heart Association (NYHA) guidelines. 12. Current, serious, clinically significant cardiac arrhythmias, defined as the existence of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V. 13. Baseline QTc >470 msec and/or previous history of QT prolongation while taking other medications. 14. Concomitant use of medications associated with a high incidence of QT prolongation is not allowed. 15. History or signs of active coronary artery disease with or without angina pectoris within the last 6 months. 16. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution’s lower limit of predicted normal. 17. Known history of HIV infection. 18. Active, clinically significant serious infection requiring treatment with antibiotics, anti-virals or anti-fungals. The Medical Monitor should be contacted for any uncertainties. 19. Major surgery within 30 days prior to date of randomization. 20. Current or past substance abuse or any condition that might interfere with the subject’s participation in the study or in the evaluation of the study results. 21. Any condition that is unstable and could jeopardize the subject’s participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective of this study is to determine the efficacy of administration of aldoxorubicin compared to investigator’s choice of treatment in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have relapsed or were refractory to prior non-adjuvant chemotherapy, as measured by progression-free survival (PFS).;Secondary Objective: The secondary objectives of this study are to evaluate the efficacy of aldoxorubicin as measured by overall survival (OS), overall response rate (ORR), disease control rate (ORR + SD at 4 months), PFS at 4 and 6 months, safety of aldoxorubicin compared to investigator's choice in this population assessed by the frequency and severity of adverse events (AEs), abnormal findings on physical examination, laboratory tests, vital signs, echocardiogram (ECHO) evaluations, electrocardiogram (ECG) results, and weight.;Primary end point(s): To evaluate PFS in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas who have relapsed or were refractory to non-adjuvant chemotherapy.;Timepoint(s) of evaluation of this end point: The primary analysis of PFS will be carried out when approximately 191 PFS events have been observed (approximately 15 months following the completion of enrollment of 400 subjects). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): 1. To evaluate OS in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas who have relapsed or were refractory to non-adjuvant chemotherapy. 2. To evaluate the objective overall response rate (ORR; RECIST 1.1 criteria) and disease control rate (ORR + stable disease at 4 months) in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas as above. 3. To evaluate the population percentage of subjects with PFS at 4 and 6 months;Timepoint(s) of evaluation of this end point: 1) The final analysis of OS will be completed when 320 OS events have occurred. 2) Tumor response will be monitored at screening, every 6 weeks from Cycle 1-Day 1 through Week 30, and then every 12 weeks until disease progression. 3) Survival follow-up by telephone will be conducted in all subjects every 12 weeks (±14 days) from the time a subject discontinues treatment or at disease progression until the subject is either lost to follow-up, passes away, withdraws consent, or the Sponsor stops the study. | — |
Countries
Australia, Bulgaria, Canada, Chile, Denmark, France, Hungary, Israel, Italy, Netherlands, Poland, Russian Federation, Spain, United Kingdom, United States
Contacts
Public ContactClinical Operations
CytRx Corporation
Outcome results
None listed